Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment

Targeted Therapies in Cancer

(2010) Sabino Ciavarella et al.   BIODRUGS

Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

(2010) Oscar Arrieta et al.   BMC CANCER

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

(2010) Zacharenia Saridaki   WORLD JOURNAL OF GASTROENTEROLOGY

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

(2009) Xia Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes

(2009) Laszlo Markasz et al.   JOURNAL OF IMMUNOTHERAPY

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy

(2009) Hye-Suk Han et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION